Capital Fund Management (CFM)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Fund Management (CFM)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-13,800	Closed	-$1.5M	–	1001
2020 Q1	$1.5M	Buy	13,800 +10,800	+360%	+$1.25M	0.02%	619
2019 Q4	$346K	Buy	+3,000	New	+$299K	﹤0.01%	1547
2018 Q4	–	Sell	-30,600	Closed	-$2.68M	–	1811
2018 Q3	$2.68M	Buy	30,600 +15,400	+101%	+$1.55M	0.01%	994
2018 Q2	$1.5M	Sell	15,200 -7,200	-32%	-$714K	0.01%	1197
2018 Q1	$2.67M	Sell	22,400 -5,700	-20%	-$735K	0.02%	906
2017 Q4	$3.57M	Buy	28,100 +26,100	+1,305%	+$3.28M	0.02%	787
2017 Q3	$235K	Buy	+2,000	New	+$171K	﹤0.01%	1393
2017 Q1	–	Sell	-7,800	Closed	-$292K	–	1434
2016 Q4	$292K	Buy	+7,800	New	+$327K	﹤0.01%	1446
2016 Q2	–	Sell	-9,000	Closed	-$565K	–	1492
2016 Q1	$565K	Buy	+9,000	New	+$598K	0.01%	1091
2014 Q2	–	Sell	-4,100	Closed	-$275K	–	1644
2014 Q1	$275K	Buy	+4,100	New	+$317K	﹤0.01%	1515
2013 Q4	–	Sell	-9,300	Closed	-$595K	–	1637
2013 Q3	$595K	Buy	+9,300	New	+$464K	0.01%	1093

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Fund Management (CFM)'s ALNY Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Alnylam Pharmaceuticals (ALNY) stake by 569% in Q1 2026, buying an estimated $40.6M and bringing the position to 140,109 shares worth $46.4M. The position accounts for 0.21% of the portfolio, ranked #86.

Capital Fund Management (CFM) first reported a position in ALNY in Q4 2013 and has held it in 14 quarters since. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Capital Fund Management (CFM) held 140,109 shares of Alnylam Pharmaceuticals worth $46.4M as of Q1 2026.
Capital Fund Management (CFM) bought 119,169 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $40.6M.
Alnylam Pharmaceuticals made up 0.21% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #86 holding.
Capital Fund Management (CFM) first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 14 quarters since.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.